Acumen Pharmaceuticals (ABOS) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Insider Sale: Chief Legal Officer & Corp Sec of $ABOS (ABOS) Sells 11,122 Shares
Quiver QuantitativeJan 7 20:01 ET
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating, Announces Target Price $12
Moomoo NewsJan 6 06:34 ET · Ratings
Acumen Pharmaceuticals to Participate in the 7th Annual Evercore ISI HealthCONx Conference
GlobeNewswireNov 26, 2024 16:00 ET
Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?
Simply Wall StNov 16, 2024 07:45 ET
BofA Securities Maintains Acumen Pharmaceuticals(ABOS.US) With Buy Rating
Moomoo NewsNov 13, 2024 10:33 ET · Ratings
Express News | Acumen Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $12 From $14
ReutersNov 13, 2024 10:14 ET

Comments

Jaguar8

Oct 31, 2024 07:20

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Innovative Trial Screening Advancements Utilizing pTau217 Assay in Phase 2 Study of Sabirnetug for Early Alzheimer’s Disease at the 17th Annual Clinical Trials on Alzheimer’s Disease
Acumen Pharmaceuticals presented data on using pTau217 assay as an efficient screening tool for their Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer's disease. The assay, with a threshold of ≥0.15 pg/mL, effectively identifie...

1

Stock_Drift

Oct 23, 2024 15:45

After Hours Ticks. 4:44pm

$Rimini Street (RMNI.US)$ $Acumen Pharmaceuticals (ABOS.US)$ $Molina Healthcare (MOH.US)$ $BioVie (BIVI.US)$ $Allakos (ALLK.US)$ $CNS Pharmaceuticals (CNSP.US)$ $GraniteShares 2x Long TSLA Daily ETF (TSLR.US)$ $Direxion Daily TSLA Bull 2X Shares (TSLL.US)$ $T-Rex 2x Long Tesla Daily Target ETF (TSLT.US)$ $Twin Vee PowerCats (VEEE.US)$ $EpicQuest Education (EEIQ.US)$ $Mobile-health Network Solutions (MNDR.US)$
📊⚡️📊

5

Jaguar8

Jul 28, 2024 07:08

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) presented new findings from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference 2024.
The research focuses on patient experiences, biomarker data, and a new ultra-sensitive assay for measuring s...

4

1

Jaguar8

Jul 11, 2024 07:00

NEWS

$Acumen Pharmaceuticals (ABOS.US)$
Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC®) 2024
Acumen Pharmaceuticals (NASDAQ: ABOS) announced it will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC) 2024. The conference will be held in Philadelphia and online ...

Jaguar8

Apr 16, 2024 07:04

$Acumen Pharmaceuticals (ABOS.US)$
NEWS
Acumen Pharmaceuticals Presents First Comprehensive Clinical and Biomarker Data for Sabirnetug (ACU193) at American Academy of Neurology 2024 Annual Meeting
Sabirnetug demonstrated a favorable safety profile with low incidence of ARIA-E in early AD participants.
Target engagement with AβOs in cerebrospinal fluid increased in a dose-dependent manner, suggesting active removal of target from the brain.
Sabirnetug treatment led to changes in CSF and plasma bio...

ABOS Acumen Pharmaceuticals

Trade Overview

Capital Trend

News

Comments